Citable filing context
MDT's research view summarizes recent SEC filing context, starting with earnings from Jun 3, 2026.
| Filed | Item | Context |
|---|---|---|
| Jun 3, 2026 | earnings | Medtronic reported Q4 revenue of $9.8 billion and full year 2026 revenue of $36.4 billion. |
| May 18, 2026 | management_change | Brett Wall departed as EVP and President, Neuroscience Portfolio; Dr. Kweli Thompson appointed to the role. |
| Apr 27, 2026 | other | Medtronic announced unauthorized data access in its IT systems on April 24, 2026. |
| Jun 3, 2026 | Guidance: diluted_non_gaap_eps | 5.90 to 6.00 |
| Jun 3, 2026 | Guidance: organic_revenue_growth | 6.75 to 7.25 |
| Mar 24, 2026 | Guidance: eps_growth | not reported to not reported |
| Jun 18, 2026 | business | Medtronic plc is a leading global healthcare technology company operating across three primary segments: Cardiovascular, Neuroscience, and Medical Surgical. A major strategic milestone is the separation of its Diabetes business (MiniMed Group, Inc.), which completed its IPO in March 2026. Within Cardiovascular, key product lines include the Micra leadless pacemaker, Evolut TAVR systems, Symplicity Spyral renal denervation for hypertension, and Affera pulsed field ablation catheters. The Neuroscience segment is anchored by the AiBLE spine technology ecosystem, Mazor robotic guidance, and Inceptiv closed-loop spinal cord stimulators. Medical Surgical highlights include the Hugo robotic-assisted surgery system and the GI Genius AI-powered endoscopy module. Products are sold globally through direct sales representatives and independent distributors. Medtronic faces intense competition, including from pharmaceutical alternatives like GLP-1s, alongside pricing pressures driven by hospital consolidation, group purchasing organizations, and volume-based procurement tenders in China. Key operational risks include a highly stringent and evolving global regulatory environment—specifically compliance with the EU Medical Device Regulation (MDR) and emerging AI frameworks—ongoing intellectual property litigation, and potential supply chain disruptions due to reliance on sole-source suppliers for critical raw materials and components. |
| Jun 18, 2026 | mda | Medtronic’s financial performance for the fiscal year ended April 24, 2026, reflects steady revenue growth driven by strong adoption of key product innovations across its core therapeutic segments. In the Diabetes division, the MiniMed 780G insulin pump system, integrated with the Guardian 4 sensor, continued to capture market share globally. Within the Cardiovascular portfolio, growth was propelled by the Micra leadless pacemaker family and the Evolut FX transcatheter aortic valve replacement system. The Neuroscience segment saw increased momentum from the Percept PC deep brain stimulation system and Mazor robotic guidance platform. Meanwhile, the Medical Surgical segment benefited from the ongoing international expansion and clinical adoption of the Hugo robotic-assisted surgery system. Geographically, emerging markets remained a key growth driver, partially offset by volume-based procurement headwinds in China. Profitability and operating margins for fiscal year 2026 were impacted by persistent inflationary pressures, elevated R&D investments in artificial intelligence, and negative foreign currency translation effects. To mitigate these macroeconomic challenges, the company executed structural cost-saving initiatives and supply chain optimization strategies. Free cash flow generation remained robust, supporting continued dividend growth and strategic tuck-in acquisitions to bolster the pipeline. |
Source: SEC EDGAR filing text and events; period Jun 3, 2026; filed Jun 3, 2026.
MDT company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.